Back to top
more

ADC Therapeutics (ADCT)

(Real Time Quote from BATS)

$2.94 USD

2.94
268,780

+0.07 (2.44%)

Updated Aug 6, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADC Therapeutics SA (ADCT) Upgraded to Buy: Here's Why

ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?

Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.

Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.

Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected

Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.

Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y

Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.

Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales

Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.

Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates

Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.